Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy K Darke

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Contemporary Clinical Trials|June 3, 2020
Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregiversVeena Shankaran, Joseph M Unger, Amy K Darke, et al.
Biostatistics (Oxford, England)|February 23, 2010
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention TrialStuart G Baker, Amy K Darke, Paul Pinsky, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 5, 2014
A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Erin E Martinez, Amy K Darke, Catherine M Tangen, et al.
JAMA Neurology|March 21, 2017
Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)Richard J Kryscio, Erin L Abner, Allison Caban-Holt, et al.
JCO Oncology Practice|July 13, 2021
Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment TrialsJulia Mo, Amy K Darke, Katherine A Guthrie, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionM Scott Lucia, Amy K Darke, Phyllis J Goodman, et al.
JCO Oncology Practice|October 4, 2021
Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical TrialsDavid Hui, Amy K Darke, Katherine A Guthrie, et al.
JNCI Cancer Spectrum|August 10, 2023
Assessment of financial screening and navigation capabilities at National Cancer Institute community oncology clinicsAri Bell-Brown, Kate Watabayashi, Debbie Delaney, et al.
Journal of the National Cancer Institute|September 14, 2012
Health-related quality-of-life findings for the prostate cancer prevention trialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
Journal of the National Cancer Institute|January 4, 2022
S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer PatientsVeena Shankaran, Joseph M Unger, Amy K Darke, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Contemporary Clinical Trials|June 3, 2020
Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregiversVeena Shankaran, Joseph M Unger, Amy K Darke, et al.
Biostatistics (Oxford, England)|February 23, 2010
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention TrialStuart G Baker, Amy K Darke, Paul Pinsky, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 5, 2014
A functional variant in NKX3.1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Erin E Martinez, Amy K Darke, Catherine M Tangen, et al.
JAMA Neurology|March 21, 2017
Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)Richard J Kryscio, Erin L Abner, Allison Caban-Holt, et al.
JCO Oncology Practice|July 13, 2021
Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment TrialsJulia Mo, Amy K Darke, Katherine A Guthrie, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemopreventionM Scott Lucia, Amy K Darke, Phyllis J Goodman, et al.
JCO Oncology Practice|October 4, 2021
Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical TrialsDavid Hui, Amy K Darke, Katherine A Guthrie, et al.
JNCI Cancer Spectrum|August 10, 2023
Assessment of financial screening and navigation capabilities at National Cancer Institute community oncology clinicsAri Bell-Brown, Kate Watabayashi, Debbie Delaney, et al.
Journal of the National Cancer Institute|September 14, 2012
Health-related quality-of-life findings for the prostate cancer prevention trialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
Journal of the National Cancer Institute|January 4, 2022
S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer PatientsVeena Shankaran, Joseph M Unger, Amy K Darke, et al.
Pageof 3